Intus

Intus (NBS20) is a clinical-stage cancer immunotherapy that utilizes DC/TC fusion technology. Developed by California Stem Cell and later acquired by NeoStem, this cell-based therapy is designed to treat metastatic melanoma by stimulating an immune response against cancer cells. At the time of its acquisition by NeoStem, Intus was considered a Phase 3-ready asset.

Brand names

Intus

Other names

Autologous Dendritic Cell-Tumor Cell ImmunotherapyAutologous Dendritic Cells Loaded with Irradiated Autologous Tumor Cells in GM-CSFAutologous dendritic cells loaded with antigen from self-renewing proliferating autologous irradiated tumor cells in GM-CSFDC-TCmelapuldencel-T